Results 61 to 70 of about 445,623 (380)

Pregnancy in pulmonary arterial hypertension [PDF]

European Respiratory Review, 2016
Despite advanced therapies, maternal mortality in women with pulmonary arterial hypertension (PAH) remains high in pregnancy and is especially high during the post-partum period. However, recent data indicates that morbidity and mortality during pregnancy and after birth have improved for PAH patients.
Karen M. Olsson, Richard N. Channick
openaire   +4 more sources

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

Molecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho, Yubin Hah, Eunsik Yun, Hye In Ka, Aram Lee, Sora Han, Dawn Lee, Sung Wook Kim, Jong Hoon Park, Byung Su Kwon, Young Yang, Jongmin Kim   +11 more
wiley   +1 more source

Structural and hemodynamic properties in murine pulmonary arterial networks under hypoxia-induced pulmonary hypertension [PDF]

arXiv, 2020
Detection and monitoring of patients with pulmonary hypertension, defined as mean blood pressure in the main pulmonary artery above 25 mmHg, requires a combination of imaging and hemodynamic measurements. This study demonstrates how to combine imaging data from microcomputed tomography (micro-CT) images with hemodynamic pressure and flow waveforms from
arxiv  

Noninvasive Estimation of Mean Pulmonary Artery Pressure Using MRI, Computer Models, and Machine Learning [PDF]

arXiv, 2023
Pulmonary Hypertension (PH) is a severe disease characterized by an elevated pulmonary artery pressure. The gold standard for PH diagnosis is measurement of mean Pulmonary Artery Pressure (mPAP) during an invasive Right Heart Catheterization. In this paper, we investigate noninvasive approach to PH detection utilizing Magnetic Resonance Imaging ...
arxiv  

Pulmonary arterial hypertension: an update [PDF]

Netherlands Heart Journal, 2011
Pulmonary arterial hypertension (PAH), defined as group 1 of the World Heart Organisation (WHO) classification of pulmonary hypertension, is an uncommon disorder of the pulmonary vascular system. It is characterised by an increased pulmonary artery pressure, increased pulmonary vascular resistance and specific histological changes.
openaire   +4 more sources

SARS‐CoV‐2 Is Linked to Brain Volume Loss in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The impact of SARS‐CoV‐2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS‐CoV‐2 infection.
Tomas Uher, Dominika Stastna, Ingrid Menkyova, Vaclav Capek, Jiri Lindner, Petra Nytrova, Jan Krasensky, Eliza Varju, Miguel D'haeseleer, Eva Kubala Havrdova, Dana Horakova, Manuela Vaneckova, Niels Bergsland   +12 more
wiley   +1 more source

Pulmonary hypertension associated with neurofibromatosis type 2

Pulmonary Circulation, 2021
Although precapillary pulmonary hypertension is a rare but severe complication of patients with neurofibromatosis type 1 (NF1), its association with NF2 remains unknown.
Hirohisa Taniguchi, Tomoya Takashima, Ly Tu, Raphaël Thuillet, Asuka Furukawa, Yoshiko Furukawa, Akio Kawamura, Marc Humbert, Christophe Guignabert, Yuichi Tamura   +9 more
doaj   +1 more source

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

European Respiratory Journal, 2017
Current European guidelines recommend periodic risk assessment for patients with pulmonary arterial hypertension (PAH). The aim of our study was to determine the association between the number of low-risk criteria achieved within 1 year of diagnosis and ...
A. Boucly, J. Weatherald, L. Savale, X. Jaïs, V. Cottin, G. Prévôt, F. Picard, P. De Groote, M. Jevnikar, E. Bergot, A. Chaouat, C. Chabanne, A. Bourdin, F. Parent, D. Montani, G. Simonneau, M. Humbert, O. Sitbon   +17 more
semanticscholar   +1 more source

Biomarkers in Pulmonary Arterial Hypertension

Diagnostics, 2022
Pulmonary arterial hypertension (PAH) is a severe medical condition characterized by elevated pulmonary vascular resistance (PVR), right ventricular (RV) failure, and death in the absence of appropriate treatment. The progression and prognosis are strictly related to the etiology, biochemical parameters, and treatment response.
Silvana Elena Hojda, Irina Camelia Chis, Simona Clichici   +2 more
openaire   +3 more sources

Management of Pulmonary Arterial Hypertension [PDF]

Current Cardiovascular Risk Reports, 2020
This review focuses on the therapeutic management and individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food and Drug Administration-approved PAH-specific therapies and various interventional and surgical options for PAH.The paradigm for the optimal management of PAH has shifted in recent years.
Emily Beck, Tara L. Jones, Irene Z. Pan, Jennalyn D. Mayeux, John J. Ryan, Joshua A. Jacobs, John Dechand, Nathan D. Hatton, Stephen H. McKellar   +8 more
openaire   +2 more sources